Kishida, Osamu <br/><br/>
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jun 2005 
 - 584-94 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s00280-004-0959-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amphiregulin<br/>Antineoplastic Agents--pharmacology<br/>Camptothecin--analogs & derivatives<br/>Cell Line, Tumor<br/>Drug Screening Assays, Antitumor<br/>EGF Family of Proteins<br/>Epidermal Growth Factor--metabolism<br/>ErbB Receptors--metabolism<br/>Gefitinib<br/>Glycoproteins--metabolism<br/>Heparin-binding EGF-like Growth Factor<br/>Humans<br/>Intercellular Signaling Peptides and Proteins--metabolism<br/>Interleukin-8--metabolism<br/>Irinotecan<br/>Phosphorylation<br/>Quinazolines--pharmacology<br/>Reactive Oxygen Species--metabolism<br/>Signal Transduction--drug effects<br/>Stomach Neoplasms--pathology<br/>Transforming Growth Factor alpha--metabolism<br/>Tyrosine--metabolism